SpringWorks Therapeutics Inc

SpringWorks Therapeutics — Investor Presentation (December 2019)

35 slides from SpringWorks Therapeutics's investor presentation, Dec 9, 2019

  1. Slide 1: Corporate Presentation December 2019

    Corporate Presentation December 2019 NASDAQ: SWTX

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to current beliefs, expectations and assumptions

  3. Slide 3: SpringWorks Therapeutics is a Clinical-Stage Targeted Oncology Company

    SpringWorks Therapeutics is a Clinical-Stage Targeted Oncology Company ? Two late-stage rare oncology programs commenced potentially registrational trials in 2019, each supported by strong clinical data Grady NF1 patient ? Three programs addressing large opportunities in genetically defined cancers

  4. Slide 4: Demonstrated Leadership Advancing Transformative Therapies

    Demonstrated Leadership Advancing Transformative Therapies Leadership Team Saqib Islam, J.D. Chief Executive Officer Jens Renstrup, M.D., MBA Chief Medical Officer Badreddin Edris, Ph.D. Chief Business Officer Frank Perier, MBA Chief Financial Officer Mary Smith, Ph.D. Senior Vice President, Clinica

  5. Slide 5: Advancing Diversified Pipeline of Targeted Oncology Programs

    Advancing Diversified Pipeline of Targeted Oncology Programs as Standalone and Combination Therapies Key Anticipated Partner / Note: Nirogacestat = PF-03084014 and Mirdametinib = PD-0325901 (both in-licensed from Pfizer). * Received Orphan Drug, Fast Track and Breakthrough Therapy Designations. † Re

  6. Slide 6: Two Potentially Registrational Trials Ongoing in Rare Oncology Indications

    Two Potentially Registrational Trials Ongoing in Rare Oncology Indications Dana Kendall Nirogacestat Gamma Secretase Inhibitor Desmoid Tumors Mirdametinib MEK Inhibitor NF1-Associated Plexiform Neurofibromas ? Clinical activity and tolerability observed in Ph2 trial in whom were heavily pre-treated)

  7. Slide 7: Three Programs Addressing Large, Genetically Defined Cancers

    Three Programs Addressing Large, Genetically Defined Cancers in Collaboration with Industry Leaders Mutations/Fusions BRAF Primary & Class 2/3 Mutations /3 Mutations F Fusions V600 Expecting to have three programs in large cancer indications in the clinic by 1Q20, each supported by strong preclinica

  8. Slide 8: Nirogacestat Desmoid Tumors

    Nirogacestat Desmoid Tumors

  9. Slide 9: Nirogacestat: A New Paradigm for Patients With Desmoid Tumors

    Nirogacestat: A New Paradigm for Patients With Desmoid Tumors Dana Desmoid patient ? Nirogacestat is an oral, selective gamma secretase inhibitor with > 9 years of clinical experience (over 200 subjects exposed) ? Clinical activity observed in Phase 1 and Phase 2 trials in desmoid tumors independent

  10. Slide 10: Desmoid Tumors are Highly Morbid Soft Tissue Tumors

    Desmoid Tumors are Highly Morbid Soft Tissue Tumors that are Poorly Responsive to Surgical Interventions and Off-Label Therapies Painful, disfiguring, and disabling condition ? French Desmoid Advocacy Group Survey (n=102): ? ? Presence of pain in 63% of patients Permanent pain in 38% of patients wit

  11. Slide 11: Initial Clinical Activity of Nirogacestat Observed in Desmoid Tumors

    Initial Clinical Activity of Nirogacestat Observed in Desmoid Tumors PHASE 1 PHASE 2 PHASE 3 All evaluable desmoid tumor patients in the study responded to nirogacestat treatment (1) Note: Disease control rate is percentage of patients experiencing objective response or stable disease on therapy as

  12. Slide 12: Encouraging Clinical Activity and Tolerability Observed in NCI-Conducted Phase 2 Trial

    Encouraging Clinical Activity and Tolerability Observed in NCI-Conducted Phase 2 Trial in a Refractory and Heavily Pre-Treated Patient Population PHASE 1 PHASE 2 PHASE 3 (treatment durations range from 50 to 60 months in these patients) - Well tolerated; only 1 discontinuation due to AE (grade 2 urt

  13. Slide 13: Double-Blind, Placebo-Controlled Phase 3 Trial (DeFi Trial) Has Commenced

    Double-Blind, Placebo-Controlled Phase 3 Trial (DeFi Trial) Has Commenced PHASE 1 PHASE 2 PHASE 3 (1) A total of 51 events will provide 90% power and a 1-sided type 1 error rate of 0.025 (1-side hypothesis) to detect a difference between nirogacestat and placebo, assuming the median PFS in the nirog

  14. Slide 14: Nirogacestat Has the Potential to Become the Standard of Care

    Nirogacestat Has the Potential to Become the Standard of Care Treatment for Desmoid Tumors Nirogacestat Uptake Nirogacestat Uptake We estimate 5,500 to 7,000 desmoid tumor patients are actively receiving treatment in the US per year Note: Treatment algorithm based on published guidelines and physici

  15. Slide 15: Nirogacestat + Belantamab Mafodotin Combination Therapy in Relapsed/Refractory Multiple Myeloma

    Nirogacestat + Belantamab Mafodotin Combination Therapy in Relapsed/Refractory Multiple Myeloma

  16. Slide 16: Advancing First-in-Class Combination of Nirogacestat with Belantamab Mafodotin

    Advancing First-in-Class Combination of Nirogacestat with Belantamab Mafodotin in Collaboration with GlaxoSmithKline Phase 1b Trial Initiating in 1Q20 and Supported by Strong Preclinical Data ~27,000 relapsed/refractory multiple myeloma patients in the US without treatment options Belantamab mafodot

  17. Slide 17: Combination Approach: Using a Gamma Secretase Inhibitor to Potentiate BCMA-Directed Therapies

    Combination Approach: Using a Gamma Secretase Inhibitor to Potentiate BCMA-Directed Therapies for the Treatment of Multiple Myeloma BCMA has emerged as a promising target in multiple myeloma ? Universally expressed on the surface of multiple myeloma cells and clinically validated across modalities G

  18. Slide 18: Nirogacestat Prevents BCMA Shedding, Upregulates BCMA Expression

    Nirogacestat Prevents BCMA Shedding, Upregulates BCMA Expression, and Shows Synergistic Cell Killing with BCMA ADC in Human MM Cell Lines Nirogacestat rapidly and significantly upregulates BCMA cell surface expression levels Nirogacestat enhances multiple myeloma cell killing activity of BCMA ADC by

  19. Slide 19: Mirdametinib NF1-Associated Plexiform Neurofibromas

    Mirdametinib NF1-Associated Plexiform Neurofibromas

  20. Slide 20: Mirdametinib: Potential Best-in-Class Therapy for Patients with NF1-PN

    Mirdametinib: Potential Best-in-Class Therapy for Patients with NF1-PN Kendall NF1 patient ? Mirdametinib is an oral, small molecule MEK1/2 inhibitor with clinical validation and over 200 subjects exposed to date Encouraging results from Phase 2 investigator-initiated trial in adolescents and adults

  21. Slide 21: Plexiform Neurofibromas Are Painful, Disfiguring Tumors

    Plexiform Neurofibromas Are Painful, Peripheral Nerve Sheaths Disfiguring Tumors That Grow Along NF1-PN are a painful and devastating condition with significant morbidities ? Mutations in NF1 gene cause loss of neurofibromin, a key repressor of the MAPK pathway, leading to uncontrolled tumor growth

  22. Slide 22: Mirdametinib: Encouraging Phase 2 Results with Potentially Differentiated Safety Profile

    Mirdametinib: Encouraging Phase 2 Results with Potentially Differentiated Safety Profile vs. Other MEK Inhibitors PHASE 2 PHASE 2B fatigue (1) and pain (1) observed with other MEK inhibitors We believe that mirdametinib has the opportunity to demonstrate a more tolerable safety profile than other ME

  23. Slide 23: Single-Arm Phase 2b Trial (ReNeu Trial) Has Commenced

    Single-Arm Phase 2b Trial (ReNeu Trial) Has Commenced PHASE 2 PHASE 2B Treatment duration and trial populations designed to demonstrate full potential of mirdametinib in NF1-PN PROPRIETARY & CONFIDENTIAL 23 Trial SummarySummary of Endpoints ? Expected to enroll ~100 patients in 2 strata (pediatrics,

  24. Slide 24: Mirdametinib + Lifirafenib Combination Therapy in RAS/RAF Mutant Solid Tumors

    Mirdametinib + Lifirafenib Combination Therapy in RAS/RAF Mutant and Other MAPK Pathway Aberrant Solid Tumors

  25. Slide 25: Advancing Potentially Best-in-Class MEK/RAF-Dimer Inhibitor Combination with BeiGene

    Advancing Potentially Best-in-Class MEK/RAF-Dimer Inhibitor Combination in Collaboration with BeiGene Phase 1b Trial Ongoing with Trial Update Expected in 2020 S pa ant area of unmet need in cancer patients with RAS/RAF mutations and other MAPK ay aberrations (approximately 25% of solid tumors) Lifi

  26. Slide 26: Combination Approach: Vertical MAPK Pathway Inhibition

    Combination Approach: Vertical RAS-Mutant Solid Tumors MAPK Pathway Inhibition to Address No currently approved targeted therapies for RAS mutant cancers ? RAS mutations account for approximately 25% of all solid tumors, >200k newly incident US patients annually Patients with RAS mutations typically

  27. Slide 27: Mirdametinib + Lifirafenib: Encouraging Monotherapy Activity and Strong Preclinical Combo Data

    Mirdametinib + Lifirafenib: Encouraging Monotherapy Activity and Strong Preclinical Combo Data Monotherapy Activity Shown in RAS and BRAF Mutant Solid Tumors Source: Desai presentation, "A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors," AACR

  28. Slide 28: Phase 1b Study Currently Enrolling Dose-Escalation Portion

    Patients Currently Being Phase 1b Study Enrolled in the Dose-Escalation Portion of the PHASE 1B and other MAPK aberrations tolerated dose/recommended Phase 2 dose (1) Recruitment of no more than 50% with CRC or pancreatic cancer. Baseline tissue from either fresh tumor or archived tissue is mandator

  29. Slide 29: BGB-3245 RAF Mutant Solid Tumors

    BGB-3245 RAF Mutant Solid Tumors

  30. Slide 30: BGB-3245: Potentially Differentiated Program for Unaddressed RAF Driver Mutations

    BGB-3245: Potentially Differentiated Program for Currently Unaddressed RAF Driver Mutations Phase 1 Dose Escalation and Expansion Trial Expected to Initiate in 1Q20 BGB-3245 is a novel RAF inhibitor being advanced in collaboration with BeiGene through Ma ure, a newly formed, jointly owned entity BGB

  31. Slide 31: The SpringWorks Opportunity

    The SpringWorks Opportunity Rylie NF1 patient

  32. Slide 32: Pipeline is Rich in Near-Term Anticipated Catalysts

    Pipeline is Rich in Near-Term Anticipated Catalysts indication selection initiation (1) Phase 1b clinical trial evaluating belantamab mafodotin in combination with nirogacestat in patients with relapsed or refractory multiple myeloma will be examined as a sub-study in GlaxoSmithKline's DREAMM-5 plat

  33. Slide 33: Financial Highlights

    Financial Highlights $228M Private Financing Proceeds $186M September 2019 IPO Proceeds $344M Cash & Cash Equivalents(1) No Debt 43.0M Common Shares Outstanding(2) PROPRIETARY & CONFIDENTIAL 33 (1) As of September 30, 2019. (2) As of November 12, 2019. Current cash position expected to fund operatio

  34. Slide 34: SpringWorks is Advancing a Diversified Portfolio of Targeted Oncology Therapies

    SpringWorks is Advancing a Diversified Portfolio of Targeted Oncology Therapies on the Path Towards Becoming a Commercial-Stage Company Operational excellence in clinical development Shared-value partnership and business development model Versatile and clinically validated product candidates Tightly

  35. Slide 35: SpringWorks

    Springworks. \

SpringWorks Therapeutics — Investor Presentation (December 2019) on 6ix